MXPA04001268A - Inhibidor de anhidrasa carbonica. - Google Patents
Inhibidor de anhidrasa carbonica.Info
- Publication number
- MXPA04001268A MXPA04001268A MXPA04001268A MXPA04001268A MXPA04001268A MX PA04001268 A MXPA04001268 A MX PA04001268A MX PA04001268 A MXPA04001268 A MX PA04001268A MX PA04001268 A MXPA04001268 A MX PA04001268A MX PA04001268 A MXPA04001268 A MX PA04001268A
- Authority
- MX
- Mexico
- Prior art keywords
- carbonic anhydrase
- drugs
- anhydrase inhibitor
- cyclooxygenase
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31156101P | 2001-08-10 | 2001-08-10 | |
| PCT/US2002/025447 WO2003013655A2 (en) | 2001-08-10 | 2002-08-09 | Carbonic anhydrase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04001268A true MXPA04001268A (es) | 2004-05-27 |
Family
ID=23207450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04001268A MXPA04001268A (es) | 2001-08-10 | 2002-08-09 | Inhibidor de anhidrasa carbonica. |
Country Status (7)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
| UA80763C2 (en) * | 2003-05-22 | 2007-10-25 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| LT5504B (lt) * | 2006-08-02 | 2008-06-25 | Biotechnologijos Institutas | Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti |
| CN102574782B (zh) * | 2009-10-21 | 2014-10-08 | 拜耳知识产权有限责任公司 | 取代的卤代苯氧基苯甲酰胺衍生物 |
| US10562859B2 (en) | 2015-07-01 | 2020-02-18 | Signalchem Lifesciences Corporation | Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1061036C (zh) * | 1993-11-30 | 2001-01-24 | G·D·瑟尔公司 | 用于治疗炎症的取代的吡唑基苯磺酰胺类化合物 |
| JP3181190B2 (ja) * | 1994-12-20 | 2001-07-03 | 日本たばこ産業株式会社 | オキサゾール誘導体 |
| US5944021A (en) * | 1995-06-07 | 1999-08-31 | Rodriguez; Victorio C. | Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema |
| CA2249009C (en) * | 1996-04-12 | 2003-09-16 | G.D. Searle & Co. | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
| US6323226B1 (en) * | 1999-10-19 | 2001-11-27 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
-
2002
- 2002-08-09 CA CA002456939A patent/CA2456939A1/en not_active Abandoned
- 2002-08-09 MX MXPA04001268A patent/MXPA04001268A/es unknown
- 2002-08-09 JP JP2003518654A patent/JP2005501083A/ja not_active Withdrawn
- 2002-08-09 AU AU2002331050A patent/AU2002331050A1/en not_active Abandoned
- 2002-08-09 WO PCT/US2002/025447 patent/WO2003013655A2/en not_active Application Discontinuation
- 2002-08-09 BR BR0211836-0A patent/BR0211836A/pt not_active IP Right Cessation
- 2002-08-09 EP EP02768491A patent/EP1414522A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005501083A (ja) | 2005-01-13 |
| EP1414522A2 (en) | 2004-05-06 |
| WO2003013655A3 (en) | 2003-08-14 |
| AU2002331050A1 (en) | 2003-02-24 |
| BR0211836A (pt) | 2004-12-14 |
| CA2456939A1 (en) | 2003-02-20 |
| WO2003013655A2 (en) | 2003-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
| WO2005009342A3 (en) | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith | |
| WO2003059271A3 (en) | Treatment involving peroxisome proliferator-activated receptor-gamma agonist and cyclooxygenase-2 selective inhibitors | |
| HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
| GB0223040D0 (en) | Therapeutic compounds | |
| JO2311B1 (en) | Alkyl inhibitors Ariel phosphodiesterase-4 | |
| WO2002098444A3 (en) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis | |
| WO2006074265A3 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
| MXPA04009352A (es) | Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2). | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| WO2004105737A3 (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents | |
| WO2008029237A3 (en) | Combination therapies for rheumatoid arthritis | |
| WO2005041864A3 (en) | Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method | |
| BRPI0411864A (pt) | combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| WO2004103283A3 (en) | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | |
| PL368971A1 (en) | Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | |
| MXPA05012358A (es) | Combinacion farmaceutica que comprende modafinilo y otra droga. | |
| WO2004073615A3 (en) | Deazaflavin compounds and methods of use thereof | |
| WO2004041191A3 (en) | Methods for the treatment, prevention and management of macular degeneration | |
| WO2005016327A3 (en) | Treatment of sleep disorders with cholinesterase inhibitors | |
| MXPA04001268A (es) | Inhibidor de anhidrasa carbonica. | |
| CA2414586A1 (en) | Agent for therapeutic treatment of optic nerve diseases and the like | |
| WO2004105699A3 (en) | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | |
| WO2005020895A3 (en) | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith | |
| WO2007117272A3 (en) | Methods for treatment of hemorrhagic shock and related disorders |